ExploreWatchlistsPricing
  1. JP-listed companies
  2. Oncolys BioPharma Inc.
  3. Financials
  4. Total assets

Oncolys BioPharma Inc. (4588)

Market cap
¥73.3B
P/E ratio
Develops viral therapies for cancer treatment and severe infections, with lead candidate OBP-301 targeting solid tumors like esophageal cancer.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndTotal assets (Million JPY)YoY (%)
Dec 31, 20254,556+42.42%
Dec 31, 20243,199+56.76%
Dec 31, 20232,041-23.02%
Dec 31, 20222,651-38.23%
Dec 31, 20214,292+53.48%
Dec 31, 20202,796-36.16%
Dec 31, 20194,380+27.69%
Dec 31, 20183,430-2.73%
Dec 31, 20173,526+12.29%
Dec 31, 20163,140-21.61%
Dec 31, 20154,006-20.02%
Dec 31, 20145,009

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat